Drug Search Results
More Filters [+]

Tonapofylline

Alternative Names: tonapofylline, bg9928
Latest Update: 2023-09-11
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: ADORA1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tonapofylline

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Heart Failure, Acute|Acute Kidney Injury|Kidney Diseases|Heart Failure

Phase 2: Heart Failure|Kidney Diseases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

POSEIDON

P2

Terminated

Heart Failure|Kidney Diseases

2010-01-01

24%

POSEIDON

P2

Terminated

Heart Failure|Kidney Diseases

2009-12-14

160HF301 , Trident I

P3

Completed

Kidney Diseases|Acute Kidney Injury|Heart Failure, Acute

2009-11-10

TRIDENT-1

P3

Completed

Heart Failure|Kidney Diseases

2009-10-30

39%

Recent News Events

Date

Type

Title